Compare ADMA Biologics Inc (ADMA) vs Atmos Energy Corporation (ATO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Atmos Energy Corporation — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Atmos Energy Corporation trades at $177.38 (market cap $29.64B). The key difference: Atmos Energy Corporation is far larger — about 13.9× ADMA Biologics Inc's market cap, and Atmos Energy Corporation pays a 2.25% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ATO | |
|---|---|---|
Market Cap | $2.13B | $29.64B |
Sector | Health | Utilities |
52-Week High | $20.38 | $192.25 |
52-Week Low | $7.60 | $151.99 |
Enterprise Value | $2.20B | $39.15B |
Dividend Yield | — | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
ATO trades at $177.58, up 0.4% today, with a bearish technical signal but neutral oscillators. Recent earnings beat expectations in Q1 2026, with revenue growth to $4.7B in 2025 and a net margin of 27.58%. The stock shows strong profitability and a P/E of 21.41, while analyst consensus is a Buy with a $188.86 target. A dividend of $1.00 was recently declared, supporting income appeal.
Outlook is positive due to earnings beats and defensive utility positioning, but risks include high capital expenditures and debt levels. Investment opportunity lies in steady growth and dividend consistency, though market volatility and interest rate sensitivity pose challenges for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →
